

182

THE UNITED STATES
TRADE MARK

GAU: 1614

FOR: METHODS OF TREATING NEUROLOGICAL CONDITIONS WITH HEMATOPOIETIC GROWTH FACTORS

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

Applicant(s) wish to disclose the following information.

☒ The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.

☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

☐ Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.

☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

■ Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.


OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. Oblon



Customer Number

22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05/03)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Wolf-Ruediger SCHAEBITZ, et al.

SERIAL NO: 10/659,295

GAU: 1614

FILED: September 11, 2003

FOR: METHODS OF TREATING NEUROLOGICAL CONDITIONS WITH HEMATOPOIETIC GROWTH FACTORS

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. Oblon


Daniel J. Pereira, Ph.D.

Registration No. 45,518

Customer Number

22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05/03)

Form PTO 1449
(Modified)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO.

242650US0CONT

SERIAL NO.

10/659,295

LIST OF REFERENCES CITED BY APPLICANT

APPLICANT

Wolf-Ruediger SCHAEBITZ, et al.

FILING DATE

September 11, 2003

GROUP

1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA	2002/151488	10/17/02	LAUFFENBURGER, et al.			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AO	03/061685	07/31/03	WIPO		
	AP	1 374 898	01/02/02	EUROPE		
	AQ	02/099081	12/12/02	WIPO		
	AR					
	AS					
	AT					
	AU					
	AV					


OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

	AW	SCHAEBITZ W. R. et al: "RECOMBINANT GRANULOCYTE-COLONY STIMULATING FACTOR (RG-CSF) IS NEUROPROTECTIVE FOLLOWING FOCAL TRANSIENT CEREBRAL ISCHEMIA AND EXCITOTOXICITY" SOCIETY FOR NEUROSCIENCE ABSTRACTS, SOCIETY FOR NEUROSCIENCE, US, Vol. 27, No. Part 2, November 10, 2001, page 2027, AN76411, XP008009334, ISSN: 0190-5295 the whole document	<input type="checkbox"/> Additional References sheet(s) attached
	AX	KONISHI Y, et al.: "TROPIC EFFECT OF ERYTHROPOIETIN AND OTHER HEMATOPOIETIC FACTORS ON CENTRAL CHOLINERGIC NEURONS IN VITRO AND IN VIVO.", BRAIN RESEARCH, April 23, 1993, Vol. 609, No.s 1-2, pages 29-35, XP001183386 ISSN: 0006-8993, Abstract, Introduction, page 29, Discussion pages 32-34	
	AY	HIERHOLZER, et al., "ACTIVATION OF STAT PROTEINS FOLLOWING ISCHEMIA REPERFUSION INJURY DEMONSTRATES A DISTINCT IL-6 AND G-CSF MEDIATED PROFILE.", TRANSPLANTATION PROCEEDINGS, SEPT. 1998, Vol. 30, No. 6, page 2647, XP001182894, ISSN: 0041-1345 the whole document	
	AZ	TIAN SHIN-SHAY, et al.: "MULTIPLE SIGNALING PATHWAYS INDUCED BY GRANULOCYTE COLONY-STIMULATING FACTOR INVOLVING ACTIVATION OF JAKs, STAT5, and/or STAT3 ARE REQUIRED FOR REGULATION OF THREE DISTINCT CLASSES OF IMMEDIATE EARLY GENES" BLOOD, Vol. 88, No. 12, 1996, pages 4435-4444 XP001183387 ISSN: 0006-4971 the whole document	

Examiner

Date Considered

*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO 1449
(Modified)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

APP. DOCKET NO.

242650US0CONT

SERIAL NO.

10/659,295

LIST OF REFERENCES CITED BY APPLICANT

APPLICANT

Wolf-Ruediger SCHAEBITZ, et al.

FILING DATE

September 11, 2003

GROUP

1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						
	BL						
	BM						
	BN						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	BO					
	BP					
	BQ					
	BR					
	BS					
	BT					
	BU					
	BV					

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

	BW	WARD ALISTER, et al., "TYROSINE-DEPENDENT AND - INDEPENDENT MECHANISMS OF STAT3 ACTIVATION BY THE HUMAN GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF) RECEPTOR ARE DIFFERENTIALLY UTILIZED DEPENDING ON G-CSF CONCENTRATION", BLOOD, Vol. 93, No. 1, January 1, 1999 pages 113-124 XP001183113, ISSN: 0006-4971 the whole document				
	BX	SCHAEBITZ, et al. "NEUROPROTECTIVE EFFECT OF GRANULOCYTE COLONY-STIMULATING FACTOR AFTER FOCAL CEREBRAL ISCHEMIA.", STROKE, Vol. 34, No. 3, March 2003, pages 745-751, XP002294803, ISSN: 0039-2399 the whole document				
	BY					
	BZ				<input type="checkbox"/> Additional References sheet(s) attached	

Examiner

Date Considered

*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.